Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 9, 2001, Pages 603-621

  Miyazawa, Yasushi ^a,c   Blum, Robert A ^b   Schentag, Jerome J ^b   Kamimura, Hidetaka ^c   Matsushima, Hiroshi ^c   Swarz, Herbert ^a   Ito, Yutaka ^a  

^a Yamanouchi USA   (United States)

^b MILLARD FILLMORE HOSPITAL   (United States)

^c ASTELLAS PHARMA INC   (Japan)

Author keywords

Hepatic insufficiency; Pharmacokinetics; Renal insufficiency; Tamsulosin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; OROSOMUCOID; TAMSULOSIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG URINE LEVEL; HEADACHE; HUMAN; KIDNEY FAILURE; LIVER FAILURE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; VERTIGO;

EID: 0034748577     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80067-9     Document Type: Article

References (30)

1. Identification, quantification and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate
2. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle
3. Alpha 1-adrenoceptor subtypes in the human prostate
4. 1A-Adrenergic receptors in the isolated human prostate
5. 1C-subtype
6. 1C-adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH)
7. 1-adrenoceptor antagonists in benign prostatic hyperplasia: Rationale and clinical experience
8. 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH)
9. 1-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH)
10. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia
11. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial
12. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia
13. 1-blocker, YM617, in the treatment of benign prostatic hypertrophy
14. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension
15. Pharmacokinetics of terazosin
16. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia
17. Pharmacokinetics of YM617 in subjects with renal insufficiency
18. Pharmacokinetics of YM617 in subjects with hepatic insufficiency
19. Sensitive method for the determination of amsulosin in human plasma using high-performance liquid chromatography with fluorescence detection
20. 1-acid glycoprotein and possibility of binding interactions
21. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis
22. Alpha-1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness
23. Altered plasma drug binding in cancer: Role of alpha1-acid glycoprotein and albumin
24. On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction
25. Alpha1-acid glycoprotein concentration and protein binding in trauma
26. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1-acid glycoprotein
27. Drug binding to human alpha-1-acid glycoprotein in health and disease
28. Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: Effects of alpha1-acid glycoprotein
29. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: An open-label single-dose and multiple-dose study